The Taiwan’s National Health Insurance (NHI) has reimbursed trastuzumab for HER2 positive BCs under several conditions: (1) One-year adjuvant and or neoadjuvant therapy for HER2-positive nodal positive early BC. Here, ERBB2 is linked to breast cancer.